Detalles de la búsqueda
1.
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
J Eur Acad Dermatol Venereol
; 30(6): 989-94, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26201313
2.
Defining drug-free remission of skin disease in patients with plaque psoriasis.
Br J Dermatol
; 182(6): 1484-1487, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705649
3.
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Br J Dermatol
; 167(3): 658-67, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22564148
4.
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
Br J Dermatol
; 167(6): 1374-81, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22897348
Resultados
1 -
4
de 4
1
Próxima >
>>